Comments
Drug firm Cadila Healthcare on Friday said it has received approval from the Mexican regulatory authority to market Lipaglyn (Saroglitazar Magnesium) used for the treatment of dyslipidemia in patients with diabetes. The company has been granted marketing approval by the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) to commercialise Lipaglyn in Mexico, Zydus said in a statement. Lipaglyn, a prescription drug, was first launched in India in September 2013, Zydus said. “Over the last several years, more than five lakh patients have been treated with Lipaglyn in India...,” it added. Shares of Cadila Healthcare fell 2.8 per cent at ₹465.25 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.